Literature DB >> 8870172

Measurement of anti-factor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates.

Y Sawamoto1, M Shima, M Yamamoto, S Kamisue, H Nakai, I Tanaka, K Hayashi, J C Giddings, A Yoshioka.   

Abstract

We have established a simple enzyme-linked immunosorbent assay (ELISA) for the detection of anti-factor IX IgG subclasses in haemophilia B patients with inhibitors. The assay was performed using immobilized purified factor IX. Specific IgG subclasses were detected by peroxidase-conjugated anti-human IgG1,2,3 and 4. Ten plasma samples from 6 haemophilia B patients with inhibitors ranging from 1.0 to 253 Bethesda Units/ml were analyzed. All samples were positive for IgG4. Six out of 10 samples were positive only for IgG4. Three samples were positive for IgG2. Five of the 6 patients had previously had allergic reactions to factor IX concentrates. Three patients had allergic episodes within the past month. Three samples from these latter patients taken on the day when the allergy had occurred showed positive also for IgG1. In later samples, however, taken at 4 days and 4 weeks respectively from two of these same patients. IgG1 was not detected. In two of the five patients in whom allergic reactions had occurred more than one month previously IgG1 was not detected. The results suggested that allergic reactions in patients with haemophilia B treated with factor IX concentrates were associated with the development of the specific IgG1 subclass of antibody to factor IX.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8870172     DOI: 10.1016/0049-3848(96)00136-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  Recurrent episodes of anaphylaxis in a patient with haemophilia B: a case report.

Authors:  Margherita Mauro; Elisa Bonetti; Rita Balter; Giovanni Poli; Simone Cesaro
Journal:  Blood Transfus       Date:  2016-04-28       Impact factor: 3.443

Review 2.  Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.

Authors:  C H Miller
Journal:  Haemophilia       Date:  2018-02-15       Impact factor: 4.287

3.  Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.

Authors:  B Boylan; A S Rice; A T Neff; M J Manco-Johnson; C L Kempton; C H Miller
Journal:  J Thromb Haemost       Date:  2016-09-17       Impact factor: 5.824

Review 4.  Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review.

Authors:  Andrea Bon; Massimo Morfini; Alessandro Dini; Francesca Mori; Simona Barni; Sottilotta Gianluca; Maurizio de Martino; Elio Novembre
Journal:  Ital J Pediatr       Date:  2015-02-19       Impact factor: 2.638

5.  Acquired hemophilia A: a frequently overlooked autoimmune hemorrhagic disorder.

Authors:  Yoshihiko Sakurai; Tomohiro Takeda
Journal:  J Immunol Res       Date:  2014-03-24       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.